Biocytogen provides integrated solutions for next-generation antibody drug development to the global
Location: United States, Massachusetts, Wakefield
Employees: 1001-5000
Phone: +1 781-587-3558
Total raised: $142M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.09.2020 | Series D | $142M | - |
Mentions in press and media 10
| Date | Title | Description |
| 21.06.2024 | Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform | BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully ... |
| 11.03.2024 | Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout | BOSTON, March 11, 2024 /PRNewswire/ -- Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and ef... |
| 24.05.2022 | Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | BEIJING, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters at the 2022 ASCO Annual Meeting, ... |
| 07.07.2021 | Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA | BOSTON and BEIJING, July 7, 2021 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing antibody drugs with independent intellectual property rights, announced that the U.S. Food and Drug Administr... |
| 23.06.2021 | Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars | BEIJING and BOSTON, June 23, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the succ... |
| 23.06.2021 | Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars | BEIJING, June 23, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful comp... |
| 25.02.2021 | Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform | |
| 25.09.2020 | Biocytogen Raises USD142M in Funding | Biocytogen, a Chinese clinical stage company, completed its series D1 funding raising USD 142m. The round was led by CMB International, with participation from investor partners PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures... |
| 24.09.2020 | Biocytogen Raises $142M | In August, Beijing Biocytogen Biotechnology Co., Ltd. announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully ... |
| 15.09.2020 | Chinese biotech firm Biocytogen bags $142m Series D+ led by CMB International | Premium Beijing-based biotechnology platform Biocytogen has announced the completion of a 970 million yuan ($142 million) Series D+ round led by returning backer CMB International, a Hong Kong-based subsidiary of China Merchants Bank. Conti... |